• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于检测结直肠癌组织和血清中甲基化 SFRP2 DNA 的 MethyLight 检测方法的性能。

Performance of a MethyLight assay for methylated SFRP2 DNA detection in colorectal cancer tissue and serum.

机构信息

1 Department of Gastroenterology, Affiliated Hospital of Xuzhou Medical University, Xuzhou Jiangsu, China.

2 School of Medical Technology, Xuzhou Medical University, Xuzhou Jiangsu, China.

出版信息

Int J Biol Markers. 2019 Mar;34(1):54-59. doi: 10.1177/1724600818820536. Epub 2019 Mar 11.

DOI:10.1177/1724600818820536
PMID:30852954
Abstract

BACKGROUND

Colorectal cancer is one of the five most common cancers in China, and its incidence is steadily increasing. An accurate and non-invasive screening method is needed to increase the population uptake of colorectal cancer screening. Secreted frizzled-related protein 2 ( SFRP2) has been found to be hypermethylated in most colorectal cancer patients, and it may fulfill the role of a non-invasive biomarker for colorectal cancer screening.

METHODS

Methylation status of SFRP2 was examined in 17 cancer tissues and paired adjacent paracancer tissues by a new SFRP2 MethyLight assay, which was also used to test the serum of 62 patients with colorectal cancer and 55 normal individuals.

RESULTS

The limit of detection of the SFRP2 MethyLight assay was about 200 pg per reaction. The SFRP2 methylation level was higher in 94.1% colorectal cancer tissues than in paired adjacent paracancer tissues ( P<0.001). The sensitivity and specificity of SFRP2 for detecting colorectal cancer in serum were 69.4% (95% confidence interval (CI) 56.2, 80.1%) and 87.3% (95% CI 74.9, 94.3%), respectively.

CONCLUSION

SFRP2 methylation in serum has the potential to be a non-invasive biomarker for colorectal cancer screening.

摘要

背景

结直肠癌是中国最常见的五种癌症之一,其发病率呈稳步上升趋势。需要一种准确且非侵入性的筛选方法来提高结直肠癌筛查的人群参与率。已发现分泌卷曲相关蛋白 2(SFRP2)在大多数结直肠癌患者中呈高甲基化状态,它可能作为结直肠癌筛查的非侵入性生物标志物发挥作用。

方法

采用新的 SFRP2 MethyLight 检测法检测 17 例癌组织和配对的癌旁组织中 SFRP2 的甲基化状态,并检测 62 例结直肠癌患者和 55 例正常人的血清。

结果

SFRP2 MethyLight 检测法的检测限约为 200 pg/反应。94.1%的结直肠癌组织中 SFRP2 的甲基化水平高于配对的癌旁组织(P<0.001)。SFRP2 对血清中结直肠癌的检测灵敏度和特异性分别为 69.4%(95%置信区间 56.2%,80.1%)和 87.3%(95%置信区间 74.9%,94.3%)。

结论

血清中的 SFRP2 甲基化有可能成为结直肠癌筛查的非侵入性生物标志物。

相似文献

1
Performance of a MethyLight assay for methylated SFRP2 DNA detection in colorectal cancer tissue and serum.用于检测结直肠癌组织和血清中甲基化 SFRP2 DNA 的 MethyLight 检测方法的性能。
Int J Biol Markers. 2019 Mar;34(1):54-59. doi: 10.1177/1724600818820536. Epub 2019 Mar 11.
2
A novel plasma based early colorectal cancer screening assay base on methylated SDC2 and SFRP2.一种基于甲基化 SDC2 和 SFRP2 的新型血浆早期结直肠癌筛查检测方法。
Clin Chim Acta. 2020 Apr;503:84-89. doi: 10.1016/j.cca.2020.01.010. Epub 2020 Jan 18.
3
Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening.粪便DNA中高甲基化的SFRP2基因是用于结直肠癌无创筛查的一种极具潜力的生物标志物。
World J Gastroenterol. 2008 Jan 28;14(4):524-31. doi: 10.3748/wjg.14.524.
4
Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas.联合检测血浆GATA5和SFRP2甲基化是结直肠癌和腺瘤有效的非侵入性生物标志物。
World J Gastroenterol. 2015 Mar 7;21(9):2629-37. doi: 10.3748/wjg.v21.i9.2629.
5
Comparison of a prototype reverse hybridization assay and MethyLight for detection of SFRP2 promotor methylation in fecal DNA.粪便DNA中SFRP2启动子甲基化检测的原型反向杂交分析与甲基化特异性荧光定量PCR法的比较
Int J Biol Markers. 2017 Oct 31;32(4):e467-e470. doi: 10.5301/ijbm.5000289.
6
Sensitive and Noninvasive Detection of Aberrant SFRP2 and MGMT-B Methylation in Iranian Patients with Colon Polyps.伊朗结肠息肉患者中异常SFRP2和MGMT-B甲基化的灵敏且无创检测
Asian Pac J Cancer Prev. 2016;17(4):2185-93. doi: 10.7314/apjcp.2016.17.4.2185.
7
Hypermethylated Promoters of Secreted Frizzled-Related Protein Genes are Associated with Colorectal Cancer.分泌型卷曲相关蛋白基因的高甲基化启动子与结直肠癌相关。
Pathol Oncol Res. 2019 Apr;25(2):567-575. doi: 10.1007/s12253-018-0505-6. Epub 2018 Oct 27.
8
Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer.分泌型卷曲相关蛋白2甲基化状态在结直肠癌中的诊断和预后价值
Clin Invest Med. 2011 Apr 1;34(2):E88-95. doi: 10.25011/cim.v34i1.15105.
9
Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer.检测粪便样本中Wnt拮抗剂基因的启动子高甲基化用于早期结直肠癌的诊断
World J Gastroenterol. 2014 May 28;20(20):6329-35. doi: 10.3748/wjg.v20.i20.6329.
10
Feasibility of Plasma-Methylated for Early Detection of Gastric Cancer.血浆甲基化 用于胃癌早期检测的可行性。
Cancer Control. 2020 Apr-Jun;27(2):1073274820922559. doi: 10.1177/1073274820922559.

引用本文的文献

1
The Role of Epigenetic Biomarkers as Diagnostic, Predictive and Prognostic Factors in Colorectal Cancer.表观遗传生物标志物在结直肠癌中作为诊断、预测和预后因素的作用
Cancers (Basel). 2025 Aug 12;17(16):2632. doi: 10.3390/cancers17162632.
2
Real-world analysis of community colorectal neoplasia screening based on stool DNA methylation detection.基于粪便DNA甲基化检测的社区结直肠肿瘤筛查的真实世界分析
Front Oncol. 2025 Jun 6;15:1562698. doi: 10.3389/fonc.2025.1562698. eCollection 2025.
3
Advances in blood DNA methylation-based assay for colorectal cancer early detection: a systematic updated review.
基于血液DNA甲基化检测的结直肠癌早期诊断研究进展:系统更新综述
Gastroenterol Hepatol Bed Bench. 2024;17(3):225-240. doi: 10.22037/ghfbb.v17i3.2978.
4
Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring.液体活检在结直肠癌中的临床应用:检测、预测及治疗监测
Mol Cancer. 2024 Jul 16;23(1):145. doi: 10.1186/s12943-024-02063-2.
5
Identification of epigenetic silencing of the SFRP2 gene in colorectal cancer as a clinical biomarker and molecular significance.鉴定结直肠癌中 SFRP2 基因的表观遗传沉默作为临床生物标志物的分子意义。
J Transl Med. 2024 May 27;22(1):509. doi: 10.1186/s12967-024-05329-x.
6
An overview of DNA methylation markers for early detection of gastric cancer: current status, challenges, and prospects.用于胃癌早期检测的DNA甲基化标志物概述:现状、挑战与前景
Front Genet. 2023 Jul 25;14:1234645. doi: 10.3389/fgene.2023.1234645. eCollection 2023.
7
Using Circulating Tumor DNA as a Novel Biomarker to Screen and Diagnose Colorectal Cancer: A Meta-Analysis.使用循环肿瘤DNA作为一种新型生物标志物筛查和诊断结直肠癌:一项荟萃分析。
J Clin Med. 2023 Jan 4;12(2):408. doi: 10.3390/jcm12020408.
8
Real-world application of a fast stool DNA test for colorectal cancer screening in primary screening positive population.用于初筛阳性人群结直肠癌筛查的快速粪便 DNA 检测的实际应用。
Cancer Med. 2023 Apr;12(7):7689-7698. doi: 10.1002/cam4.5521. Epub 2022 Dec 5.
9
Clinical Applications of Liquid Biopsy in Colorectal Cancer Screening: Current Challenges and Future Perspectives.液体活检在结直肠癌筛查中的临床应用:当前挑战与未来展望。
Cells. 2022 Nov 4;11(21):3493. doi: 10.3390/cells11213493.
10
The Interaction Between Epigenetic Changes, EMT, and Exosomes in Predicting Metastasis of Colorectal Cancers (CRC).表观遗传变化、上皮-间质转化与外泌体在预测结直肠癌转移中的相互作用
Front Oncol. 2022 May 30;12:879848. doi: 10.3389/fonc.2022.879848. eCollection 2022.